US20030220341A1 - Chemokine receptor binding heterocyclic compounds with enhanced efficacy - Google Patents

Chemokine receptor binding heterocyclic compounds with enhanced efficacy Download PDF

Info

Publication number
US20030220341A1
US20030220341A1 US10/329,329 US32932902A US2003220341A1 US 20030220341 A1 US20030220341 A1 US 20030220341A1 US 32932902 A US32932902 A US 32932902A US 2003220341 A1 US2003220341 A1 US 2003220341A1
Authority
US
United States
Prior art keywords
mmol
compound
solution
stirred
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/329,329
Other languages
English (en)
Inventor
Gary Bridger
Renato Skerlj
Ai Kaller
Curtis Harwig
David Bogucki
Trevor Wilson
Jason Crawford
Ernest McEachern
Bem Atsma
Siqiao Nan
Yuanxi Zhou
Dominique Schols
Christopher Smith
Maria Di Fluri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anormed Inc
Original Assignee
Anormed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10/329,329 priority Critical patent/US20030220341A1/en
Application filed by Anormed Inc filed Critical Anormed Inc
Priority to US10/457,034 priority patent/US7354932B2/en
Assigned to ANORMED, INC. reassignment ANORMED, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SCHOLS, DOMINIQUE, BOGUCKI, DAVID, CRAWFORD, JASON, SMITH, CHRISTOPHER DENNIS, ATSMA, BEM, BRIDGER, GARY, DIFLURI, MARIA ROSARIA, HARWIG, CURTIS, KALLER, AL, MCEACHERN, ERNEST J., NAN, SIQIAO, SKERLJ, RENATO, WILSON, TREVOR R., ZHOU, YUANXI
Publication of US20030220341A1 publication Critical patent/US20030220341A1/en
Priority to US11/301,725 priority patent/US7354934B2/en
Priority to US12/036,187 priority patent/US20080167341A1/en
Priority to US13/358,041 priority patent/US8778967B2/en
Priority to US14/302,828 priority patent/US20150038509A1/en
Priority to US15/018,698 priority patent/US10322111B2/en
Priority to US16/380,365 priority patent/US20200000774A1/en
Priority to US17/574,674 priority patent/US20220409589A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings

Definitions

  • HIV initially binds via its gp120 envelope protein to the CD4 receptor of the target cell.
  • HIV-1 isolates arising subsequently in the infection bind to the CXCR-4 chemokine receptor.
  • chemokine receptors may be the primordial obligate receptors for immunodeficiency retroviruses.
  • COMPOUND 45 Preparation of N′-(1H-benzimidazol-2-ylmethyl)-3-methyl-3-phenyl-N′-(5,6,7,8-tetrahydro-quinolin-8-yl)-butane-1,4-diamine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
US10/329,329 2001-12-21 2002-12-23 Chemokine receptor binding heterocyclic compounds with enhanced efficacy Abandoned US20030220341A1 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
US10/329,329 US20030220341A1 (en) 2001-12-21 2002-12-23 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US10/457,034 US7354932B2 (en) 2001-12-21 2003-06-06 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US11/301,725 US7354934B2 (en) 2001-12-21 2005-12-13 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US12/036,187 US20080167341A1 (en) 2001-12-21 2008-02-22 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US13/358,041 US8778967B2 (en) 2001-12-21 2012-01-25 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US14/302,828 US20150038509A1 (en) 2001-12-21 2014-06-12 Chemokine Receptor Binding Heterocyclic Compounds With Enhanced Efficacy
US15/018,698 US10322111B2 (en) 2001-12-21 2016-02-08 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US16/380,365 US20200000774A1 (en) 2001-12-21 2019-04-10 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US17/574,674 US20220409589A1 (en) 2001-12-21 2022-01-13 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34271601P 2001-12-21 2001-12-21
US35082202P 2002-01-17 2002-01-17
US10/329,329 US20030220341A1 (en) 2001-12-21 2002-12-23 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US44617003A Continuation-In-Part 2001-12-21 2003-05-23

Publications (1)

Publication Number Publication Date
US20030220341A1 true US20030220341A1 (en) 2003-11-27

Family

ID=26993156

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/329,329 Abandoned US20030220341A1 (en) 2001-12-21 2002-12-23 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US11/301,725 Expired - Lifetime US7354934B2 (en) 2001-12-21 2005-12-13 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/301,725 Expired - Lifetime US7354934B2 (en) 2001-12-21 2005-12-13 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Country Status (17)

Country Link
US (2) US20030220341A1 (zh)
EP (1) EP1465889B1 (zh)
JP (1) JP4556020B2 (zh)
KR (1) KR20040068339A (zh)
CN (2) CN1596255A (zh)
AU (1) AU2002357379A1 (zh)
BR (1) BRPI0215050B8 (zh)
CA (1) CA2467718C (zh)
ES (1) ES2623982T3 (zh)
HU (1) HUP0402458A2 (zh)
IL (2) IL161784A0 (zh)
MX (1) MXPA04006136A (zh)
NO (1) NO20042578L (zh)
NZ (1) NZ533542A (zh)
PL (1) PL369856A1 (zh)
RU (1) RU2325387C2 (zh)
WO (1) WO2003055876A1 (zh)

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20040019058A1 (en) * 2001-12-21 2004-01-29 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US20050215545A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
EP1613613A2 (en) * 2003-04-11 2006-01-11 Anormed Inc. Cxcr4 chemokine receptor binding compounds
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
WO2006028896A3 (en) * 2004-09-02 2006-04-27 Smithkline Beecham Corp Chemical compounds
EP1730113A1 (en) * 2004-03-15 2006-12-13 Anormed Inc. Process for the synthesis of a cxcr4 antagonist
US7354934B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20090169567A1 (en) * 2005-11-18 2009-07-02 Ono Pharmaceutical Co., Ltd., Basic group-containing compound and use thereof
US20090192182A1 (en) * 2006-05-16 2009-07-30 Ono Pharmaceutical Co.,Ltd. Compound having acidic group which may be protected, and use thereof
US20100261641A1 (en) * 2003-04-18 2010-10-14 Ono Pharmaceutical Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
EP2397148A2 (en) 2006-02-02 2011-12-21 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
WO2012041860A1 (en) 2010-09-27 2012-04-05 Bioprojet Benzazole derivatives as histamine h4 receptor ligands
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11357742B2 (en) * 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
CN1329374C (zh) * 2004-06-09 2007-08-01 上海靶点药物有限公司 作为ccr5拮抗剂的化合物
US20080096861A1 (en) * 2004-08-02 2008-04-24 Smithkline Beecham Corporation Chemical Compounds
WO2006038989A1 (en) * 2004-09-29 2006-04-13 Chemocentryx, Inc. Substituted arylamides
TW200619206A (en) * 2004-09-29 2006-06-16 Anormed Inc Chemokine-binding heterocyclic compound salts, and methods of use thereof
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
AU2006280945A1 (en) * 2005-08-19 2007-02-22 Genzyme Corporation Methods to enhance chemotherapy
US20080234318A1 (en) * 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7999107B2 (en) 2007-01-31 2011-08-16 Merck Sharp & Dohme Corp. Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators
WO2009032661A1 (en) * 2007-08-29 2009-03-12 Sanofi-Aventis Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
CA2718618A1 (en) * 2008-03-28 2009-10-01 Altiris Therapeutics Chemokine receptor modulators
TW201026695A (en) 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
PA8851101A1 (es) 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
US8877934B2 (en) * 2010-09-29 2014-11-04 Intervet Inc. N-heteroaryl compounds
EP2794626B3 (en) 2011-12-22 2020-08-05 GlycoMimetics, Inc. E-selectin antagonist compounds
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
CN103694142A (zh) * 2013-11-28 2014-04-02 浙江科技学院 4-N-Boc-氨基环己酮的制备方法
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
WO2017151708A1 (en) 2016-03-02 2017-09-08 Glycomimetics, Inc. Methods for the treatment and/or prevention of cardiovescular disease by inhibition of e-selectin
WO2017216373A1 (en) * 2016-06-16 2017-12-21 Centre National De La Recherche Scientifique Cxcr4 receptor-binding compounds useful for increasing interferon level
US11433086B2 (en) 2016-08-08 2022-09-06 Glycomimetics, Inc. Combination of T-cell checkpoint inhibitors with inhibitors of e-selectin or CXCR4, or with heterobifunctional inhibitors of both E-selectin and CXCR4
CN106478367B (zh) * 2016-09-30 2019-01-11 兰州大学 一种合成氯胺酮的中间体化合物以及氯胺酮的合成方法
AU2017341065B2 (en) 2016-10-07 2023-04-06 Glycomimetics, Inc. Highly potent multimeric E-selectin antagonists
IL269379B (en) * 2017-02-21 2022-06-01 Univ Emory cxcr4 receptor modulators and related uses
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2019108750A1 (en) 2017-11-30 2019-06-06 Glycomimetics, Inc. Methods of mobilizing marrow infiltrating lymphocytes and uses thereof
CN111655261A (zh) * 2017-12-19 2020-09-11 X4 制药有限公司 非环状cxcr4抑制剂和其用途
AU2018395417B2 (en) 2017-12-29 2023-07-13 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
EP3761994A1 (en) 2018-03-05 2021-01-13 GlycoMimetics, Inc. Methods for treating acute myeloid leukemia and related conditions
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PANTROPIC ENTRY INHIBITORS
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
CN111777529A (zh) * 2019-04-03 2020-10-16 复旦大学 一种1，4/1，5-氨基醇化合物及其制备方法
AU2021265602A1 (en) 2020-05-01 2023-01-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and ORF3 inhibitors as anti-covid-19 agents
WO2022113069A1 (en) 2020-11-24 2022-06-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. E protein channel blockers and orf3 inhibitors as anti-covid-19 agents
CN112142673B (zh) * 2020-09-18 2023-06-30 聊城大学 芳基烯烃唑类衍生物及其制备方法和用途
CN112898178A (zh) * 2021-01-25 2021-06-04 蚌埠产品质量监督检验研究院 一种N-Boc-反式-1,4-环己二胺的制备方法
WO2022220725A1 (en) 2021-04-16 2022-10-20 Edouard Zamaratski Lpxh inhibitors as anti-infective agents
US11931360B2 (en) * 2021-06-23 2024-03-19 Wayne State University Compositions and methods relating to inhibitors of pro-inflammatory factors for treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055054A1 (en) * 2000-12-11 2003-03-20 Tularik, Inc. CXCR3 antagonists
US20030069234A1 (en) * 2001-06-06 2003-04-10 Medina Julio C. CXCR3 antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US69234A (en) * 1867-09-24 James w
US20341A (en) * 1858-05-25 Carpet-fastener
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
US4933447A (en) * 1987-09-24 1990-06-12 Ss Pharmaceutical Co., Ltd. Quinoline derivatives
US5021409A (en) 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
US6001826A (en) 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
GB9126677D0 (en) 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
GB9400411D0 (en) 1994-01-11 1994-03-09 Johnson Matthey Plc Improvements in chemical compounds
GB9511357D0 (en) 1995-06-06 1995-08-02 Johnson Matthey Plc Improved antiviral compounds
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
AU775123B2 (en) * 1999-03-24 2004-07-15 Anormed Inc. Chemokine recpetor binding heterocyclic compounds
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
DE60137944D1 (de) * 2000-09-15 2009-04-23 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
AU2001294628B2 (en) * 2000-09-15 2007-06-07 Anormed Inc. Chemokine receptor binding heterocyclic compounds
DE60137435D1 (de) * 2000-09-15 2009-03-05 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
CN102302493B (zh) 2001-07-31 2015-08-12 健赞股份有限公司 活化祖细胞/干细胞的方法
EP1465889B1 (en) 2001-12-21 2017-03-22 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030055054A1 (en) * 2000-12-11 2003-03-20 Tularik, Inc. CXCR3 antagonists
US20030069234A1 (en) * 2001-06-06 2003-04-10 Medina Julio C. CXCR3 antagonists

Cited By (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040019058A1 (en) * 2001-12-21 2004-01-29 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354932B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20080167341A1 (en) * 2001-12-21 2008-07-10 Gary Bridger Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7354934B2 (en) 2001-12-21 2008-04-08 Anormed, Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US10322111B2 (en) 2001-12-21 2019-06-18 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US8778967B2 (en) 2001-12-21 2014-07-15 Genzyme Corporation Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20040014744A1 (en) * 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20060030557A1 (en) * 2002-04-05 2006-02-09 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US7863293B2 (en) 2003-04-11 2011-01-04 Genzyme Corporation CXCR4 chemokine receptor binding compounds
EP1613613A2 (en) * 2003-04-11 2006-01-11 Anormed Inc. Cxcr4 chemokine receptor binding compounds
EP1613613A4 (en) * 2003-04-11 2009-03-25 Anormed Inc CXCR4-CHEMOKIN RECEPTOR BINDING COMPOUNDS
US20080255197A1 (en) * 2003-04-11 2008-10-16 Bridger Gary J Cxcr4 chemokine receptor binding compounds
US20100261641A1 (en) * 2003-04-18 2010-10-14 Ono Pharmaceutical Co., Ltd. Spiro-piperidine compounds and medicinal use thereof
WO2004106493A3 (en) * 2003-05-23 2005-08-25 Anormed Inc Chemokine receptor binding heterocyclic compounds with enhanced efficacy
WO2004106493A2 (en) * 2003-05-23 2004-12-09 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1730113A1 (en) * 2004-03-15 2006-12-13 Anormed Inc. Process for the synthesis of a cxcr4 antagonist
EP1730113A4 (en) * 2004-03-15 2009-12-02 Anormed Inc PROCESS FOR SYNTHESIS OF A CXCR4 ANTAGONIST
US20050215545A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US20050215544A1 (en) * 2004-03-24 2005-09-29 Pin-Fang Lin Methods of treating HIV infection
US7776863B2 (en) * 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US20080045537A1 (en) * 2004-08-16 2008-02-21 Kristjan Gudmundsson Chemical Compounds
WO2006023400A3 (en) * 2004-08-16 2006-06-08 Smithkline Beecham Corp Chemical compounds
WO2006023400A2 (en) * 2004-08-16 2006-03-02 Smithkline Beecham Corporation Chemical compounds
US20080009495A1 (en) * 2004-08-27 2008-01-10 Ono Pharmaceutical Co., Ltd. Compound Containing Basic Group and Use Thereof
US7951816B2 (en) 2004-08-27 2011-05-31 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
US20110142856A1 (en) * 2004-08-27 2011-06-16 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
WO2006022454A1 (ja) * 2004-08-27 2006-03-02 Ono Pharmaceutical Co., Ltd 塩基性基を含有する化合物およびその用途
US8822459B2 (en) 2004-08-27 2014-09-02 Ono Pharmaceutical Co., Ltd. Compound containing basic group and use thereof
US20070232615A1 (en) * 2004-09-02 2007-10-04 Kristian Gudmundsson Chemical Compounds
WO2006028896A3 (en) * 2004-09-02 2006-04-27 Smithkline Beecham Corp Chemical compounds
US8519124B2 (en) 2005-11-18 2013-08-27 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
US20090169567A1 (en) * 2005-11-18 2009-07-02 Ono Pharmaceutical Co., Ltd., Basic group-containing compound and use thereof
US8168783B2 (en) 2005-11-18 2012-05-01 Ono Pharmaceutical Co., Ltd. Chemokine receptor antagonists and use thereof
EP2407171A2 (en) 2006-02-02 2012-01-18 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
EP2397148A2 (en) 2006-02-02 2011-12-21 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
US20090192182A1 (en) * 2006-05-16 2009-07-30 Ono Pharmaceutical Co.,Ltd. Compound having acidic group which may be protected, and use thereof
WO2012041860A1 (en) 2010-09-27 2012-04-05 Bioprojet Benzazole derivatives as histamine h4 receptor ligands
US10953003B2 (en) 2015-12-14 2021-03-23 X4 Pharmaceuticals, Inc. Methods for treating cancer
US11357742B2 (en) * 2015-12-14 2022-06-14 X4 Pharmaceuticals, Inc. Methods for treating cancer
WO2017106630A1 (en) 2015-12-18 2017-06-22 The General Hospital Corporation Polyacetal polymers, conjugates, particles and uses thereof
US10610527B2 (en) 2015-12-22 2020-04-07 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11219621B2 (en) 2015-12-22 2022-01-11 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
US10759796B2 (en) 2016-06-21 2020-09-01 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11780837B2 (en) 2016-06-21 2023-10-10 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11306088B2 (en) 2016-06-21 2022-04-19 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
US11332470B2 (en) 2016-06-21 2022-05-17 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
WO2018106738A1 (en) 2016-12-05 2018-06-14 Massachusetts Institute Of Technology Brush-arm star polymers, conjugates and particles, and uses thereof
US11045461B2 (en) 2018-08-31 2021-06-29 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US11672793B2 (en) 2018-08-31 2023-06-13 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use

Also Published As

Publication number Publication date
KR20040068339A (ko) 2004-07-30
CA2467718A1 (en) 2003-07-10
NZ533542A (en) 2007-04-27
CN1596255A (zh) 2005-03-16
JP2005518397A (ja) 2005-06-23
ES2623982T3 (es) 2017-07-12
AU2002357379A1 (en) 2003-07-15
CN102153540A (zh) 2011-08-17
WO2003055876A1 (en) 2003-07-10
BRPI0215050B8 (pt) 2021-05-25
HUP0402458A2 (hu) 2005-07-28
RU2325387C2 (ru) 2008-05-27
IL161784A0 (en) 2005-11-20
EP1465889A4 (en) 2008-05-14
RU2004122406A (ru) 2006-01-20
BR0215050B1 (pt) 2017-11-14
MXPA04006136A (es) 2004-11-01
BR0215050A (pt) 2004-10-13
EP1465889B1 (en) 2017-03-22
IL161784A (en) 2011-07-31
JP4556020B2 (ja) 2010-10-06
PL369856A1 (en) 2005-05-02
US20060100240A1 (en) 2006-05-11
US7354934B2 (en) 2008-04-08
EP1465889A1 (en) 2004-10-13
NO20042578L (no) 2004-09-07
CA2467718C (en) 2011-04-26

Similar Documents

Publication Publication Date Title
US10322111B2 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US20030220341A1 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
US7629337B2 (en) Chemokine receptor binding heterocyclic compounds
US6750348B1 (en) Chemokine receptor binding heterocyclic compounds
AU2001294628B2 (en) Chemokine receptor binding heterocyclic compounds
RU2289581C2 (ru) Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение
US20220409589A1 (en) Chemokine receptor binding heterocyclic compounds with enhanced efficacy
RU2277092C2 (ru) Гетероциклические соединения, их применение и фармацевтическая композиция для лечения состояний, опосредованных схсr4 и ccr5

Legal Events

Date Code Title Description
AS Assignment

Owner name: ANORMED, INC., BRITISH COLUMBIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BRIDGER, GARY;SKERLJ, RENATO;KALLER, AL;AND OTHERS;REEL/FRAME:014171/0639;SIGNING DATES FROM 20030508 TO 20030515

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION